Payment overview · 2025
General Payments
$318.10
16 reported records · 13 companies
Healthcare provider profile · identity verified
Steven J Spencer, MD
Allopathic & Osteopathic Physicians|Family Medicine · MAGNA, UT · NPI 1356369938
Verified facts
What the public records show
CMS Open Payments records show Steven J Spencer, MD received $318.10 in general payments during 2025 across 16 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.83 | 17.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.37 | 13.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.10 | 9.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.74 | 7.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.57 | 7.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.46 | 7.4% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.42 | 7.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.55 | 6.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.75 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.91 | 5.3% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $14.75 | 4.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.01 | 4.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.64 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.10 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.83 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 503 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 105 |
| Metformin Hcl | Metformin Hcl | 382 | 112 |
| Lisinopril | Lisinopril | 331 | 98 |
| Losartan Potassium | Losartan Potassium | 329 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 304 | 79 |
| Tramadol Hcl | Tramadol Hcl | 259 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 37 |
| Simvastatin | Simvastatin | 206 | 56 |
| Gabapentin | Gabapentin | 205 | 63 |
| Alprazolam | Alprazolam | 185 | 27 |
| Metformin Hcl Er | Metformin Hcl | 181 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 45 |
| Potassium Chloride | Potassium Chloride | 165 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 26 |
| Clonazepam | Clonazepam | 156 | 18 |
| Furosemide | Furosemide | 151 | 41 |
| Eliquis | Apixaban | 149 | 37 |
| Ibuprofen | Ibuprofen | 149 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 127 | 44 |
| Trazodone Hcl | Trazodone Hcl | 117 | 37 |
| Glimepiride | Glimepiride | 112 | 32 |
| Famotidine | Famotidine | 108 | 22 |
| Montelukast Sodium | Montelukast Sodium | 107 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 26 |
| Lorazepam | Lorazepam | 95 | 15 |
| Alendronate Sodium | Alendronate Sodium | 92 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 25 |
| Jardiance | Empagliflozin | 90 | 25 |
| Meloxicam | Meloxicam | 89 | 26 |
| Carvedilol | Carvedilol | 84 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Spironolactone | Spironolactone | 63 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 11 |
| Fenofibrate | Fenofibrate | 60 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 23 |
| Donepezil Hcl | Donepezil Hcl | 50 | 15 |
| Allopurinol | Allopurinol | 46 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 11 |
| Azithromycin | Azithromycin | 43 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 19 |
| Sertraline Hcl | Sertraline Hcl | 35 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Prednisone | Prednisone | 34 | 27 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.10 · 16 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, FARXIGA, Fluad, Flucelvax, GVOKE HYPOPEN, INSPIRE, MOUNJARO, REXULTI, SAPIEN 3 Ultra RESILIA, SLYND, VOQUEZNA, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error